FDA grants accelerated approval to GSK's Nelkarmi for previously treated ALK-positive lung cancer

In brief

AI-generated, editorially reviewed

  • GSK's Nelkarmi received accelerated FDA approval for previously treated ALK-positive non-small cell lung cancer in adults.
  • Eligible patients must have received alectinib only or at least two prior ALK inhibitors plus platinum-based chemotherapy.
  • The approval was granted ahead of the FDA's November 27, 2026, target date.

Description

(AWP Alliance News) - The FDA granted accelerated approval to GSK's Nelkarmi (neladalkib) for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer. Eligible patients must have received alectinib as their only prior ALK inhibitor, or at least two prior ALK inhibitors plus platinum-based chemotherapy.

The decision came ahead of the FDA's November 27, 2026, target date.

Disclaimer: This news brief was created using generative artificial intelligence. GSK plc published the original content used to generate this news brief via RNS, the regulatory disclosure system operated by the London Stock Exchange, on November 18, 2026, and is solely responsible for the information contained therein.